Technology Bundle ID: TAB-3014

Albumin Binding Immunomodulatory Compositions

Request More Info
Licensing Contact:
Primary Inventors: 
Xiaoyuan Chen (NIBIB)
Co-Inventors: 
Guizhi Zhu (NIBIB)
Development Stage: 
Discovery
Development Status: 

Early-stage

Institute or Center: 
NIBIB

The invention relates to molecules wherein Evan’s Blue dye is chemically conjugated to CpG Oligonucleotides that elicit anti-tumoral or infection fighting immunity. Evans Blue, a symmetric azo dye, has high binding affinity to albumin. Albumin binding ability of Evans blue is utilized with CpGs and tumor-specific antigens, in order to leverage endogenous albumin that increases the safety and the potency of molecular vaccines. As such, the molecular entities provided here enable efficient delivery and prolonged retention in lymph nodes and reduce systemic toxicity of Evans Blue and enhanced the therapeutic potency of molecular vaccines.

Applications:
  • Cancer therapeutics
  • Infectious disease therapeutics
  • Lymph node specificity
  • Higher stability/Lower toxicity

Patents

PCT Application PCT/US2017/031098
Filed on 2017-05-04
US Application 16/098,115
Filed on 2018-10-31
US Application 62/331,890
Filed on 2016-05-04

Updated

Jun 22, 2016

Data Source: 
tts